ARCA biopharma Statistics Share Statistics ARCA biopharma has 1.21M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 1.21M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) 99.99% Shares Floating 4.79M Failed to Deliver (FTD) Shares 1 FTD / Avg. Volume 0.01%
Short Selling Information The latest short interest is 5.31M, so 0% of the outstanding
shares have been sold short.
Short Interest 5.31M Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 11.06
Valuation Ratios The PE ratio is -55.08 and the forward
PE ratio is null.
ARCA biopharma's PEG ratio is
1.19.
PE Ratio -55.08 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 7.94 P/FCF Ratio -58.65 PEG Ratio 1.19
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for ARCA biopharma.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 59.01,
with a Debt / Equity ratio of 0.01.
Current Ratio 59.01 Quick Ratio 59.01 Debt / Equity 0.01 Debt / EBITDA -0.04 Debt / FCF -0.06 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.78M Employee Count 3 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -12.41% in the
last 52 weeks. The beta is 0.9, so ARCA biopharma's
price volatility has been higher than the market average.
Beta 0.9 52-Week Price Change -12.41% 50-Day Moving Average 39.48 200-Day Moving Average 30.66 Relative Strength Index (RSI) 34.32 Average Volume (20 Days) 13,857
Income Statement
Revenue n/a Gross Profit -111K Operating Income -7.3M Net Income -5.34M EBITDA -7.3M EBIT n/a Earnings Per Share (EPS) -0.37
Full Income Statement Balance Sheet The company has 37.43M in cash and 280K in
debt, giving a net cash position of 37.15M.
Cash & Cash Equivalents 37.43M Total Debt 280K Net Cash 37.15M Retained Earnings -188.74M Total Assets 377.11M Working Capital 340.36M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -5.01M
and capital expenditures 0, giving a free cash flow of -5.01M.
Operating Cash Flow -5.01M Capital Expenditures n/a Free Cash Flow -5.01M FCF Per Share -0.35
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields ABIO does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for ABIO.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Sep 3, 2024. It was a
backward
split with a ratio of 1:12.
Last Split Date Sep 3, 2024 Split Type backward Split Ratio 1:12
Scores Altman Z-Score 1.85 Piotroski F-Score 1
